Podcasts about Cyclophosphamide

Welcome back Rounds Table Listeners!We are back today with a solo episode with Dr. John Fralick!This week, he will discuss a paper exploring infliximab versus cyclophosphamide for the treatment of severe Behçet's Syndrome. Here we go!Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome (0:00 – 5:15).And for the Good Stuff:Bob Ross and Painting (5:15 – 6:28).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePodsDo you ever feel like you can't get ahead of charting? Freed AI has an AI driven scribe for you! You can try Freed for free right now by going to getfreed.ai. Listeners can use the INTERN50 code for $50 off their first month!

When should we choose rituximab over cyclophosphamide? What role can avacopan play as an adjunct therapy? When is plasma exchange a viable option? How can we effectively navigate steroid tapering? These are just a few of the critical questions we'll explore with our next guest, Dr. Tanaz Kermani, founder and director of the Vasculitis Program at UCLA, a dedicated clinician and active researcher. Join us as we delve into these topics and address the challenges of diagnosing and managing patients with vasculitis. 

In this week's episode we'll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Featured Articles:Decitabine in older patients with AML: Quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase III trial Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice Outcomes of HLA-mismatched HSCT with TCRab/CD19 depletion or post-HSCT cyclophosphamide for inborn errors or immunity 

Kevin Campbell, MD, a pediatric oncologist at Children's Mercy Kansas City and Clinical Assistant Professor of Pediatrics, University of Missouri-Kansas City School of Medicine discusses results from the Phase 1 study assessing the safety and toxicity of cabozantinib in combination with topotecan and cyclophosphamide for relapsed osteosarcoma and Ewing sarcoma.Dr. Kevin Campbell is a pediatric oncologist at Children's Mercy Kansas City and a Clinical Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine.  He has an interest in clinical trials relevant to children with solid tumors, with an emphasis on neuroblastoma and sarcomas. During his training at Dana-Farber Cancer Institute/Boston Children's Hospital and now extending into his career as an attending, his research focuses on clinical outcomes for patients with high-risk or advanced solid tumors and the development and implementation of early phase clinical trials with novel agents or combinations of agents to improve outcomes.His work to advance clinical trials includes experience in multiple spheres.  He has completed specific training in the writing, development and management of early phase clinical trials and currently has a phase I clinical trial open which he developed. His work also involves the analysis of biomarkers that have been incorporated into national phase II and phase III clinical trials.

Expert: Sofiko Sharashenidze, Mardaleishvili Medical Centre, Tbilisi, Georgia

The EMEUNET "What is New?" podcast is back! Join Philipp Bosch and Pierre-Antoine Juge as they discuss hot topics in rheumatology with special guests. If you are too busy to read the EMEUNET What Is New contributions (⁠⁠https://emeunet.eular.org/what_is_new.cfm⁠⁠), this podcast is exactly for you. Now you can get updated while on the go, with highlights of the most recent publications in the field of Rheumatology, selected for you by EMEUNET members. Cyclophosphamide or Rituximab for interstitial lung disease in connective tissue disease? Learn about the newest results from the RECITAL trial with our guest Prof. Toby Maher.

Get our free download! Implementing AMA Style – 8 Things to Get Right Here are the highlights of this week's episode: ·      The FDA granted traditional approval to Leqembi, an Alzheimer's treatment manufactured by Eisai and Biogen. The approval, based on phase 3 data demonstrating reduced cognitive decline in early Alzheimer's patients, makes Leqembi the first approved drug in its class, offering new treatment possibilities for the 6.5 million Alzheimer's patients in the US. ·      Abbott's Aveir™ DR Dual Chamber Leadless Pacemaker is the first dual chamber leadless pacemaker system for individuals with abnormal or slow heart rhythms. Utilizing the body's natural conductive properties, the device offers more efficient battery usage compared to other communication technologies and reduces the risk of complications associated with traditional pacemakers due to its minimally invasive implantation procedure. ·      The FDA approved a liquid formulation of the cancer drug cyclophosphamide. The new formulation, manufactured by Nevakar, is available in two doses and offers advantages over current powdered forms, including increased stability and reduced risk of dosing errors. ·      Amneal Pharmaceuticals received a Complete Response Letter from the FDA regarding IPX203 for Parkinson's disease. While this extended-release formation of carbidopa/levodopa shows promise with more effective therapeutic benefits than current formulations, the FDA requested additional safety information on a component of the drug, carbidopa. Amneal will continue working with the FDA to address its concerns. Please check back every Monday morning for last week's approvals so that you can stay up to date.  Visit our podcast page here. This podcast is brought to you by Nascent Medical. If you're a project manager at a CME or medical communications agency and need on-call medical writing assistance please visit Nascent Medical. We are a team of MD- and PhD-level medical writers and can create slide decks, white papers, ad board summaries, manuscripts, needs assessments, and much more. We also do medical editing using AMA style and factchecking. Visit nascentmc.com Intro and outro music Garden Of Love by Pk jazz Collective  

Picture this: it's day 1 of fellowship and your attending needs you to "get consent for treatment." Huh? How do you educate your patient? We share our tips! In this episode, we discuss important considerations, including “does my patient need a port?”, “what if drugs extravasate?”, “how do I keep side effects of drug classes straight?!” *The resources we share are our OWN opinions. Naming of resources are not endorsements. We are not sponsored by any of these entities. Pharmacology 101: * Irritant vs. Vesicant:** Each drug is deemed one of these based on the degree of tissue damage that can result if drug extravasates under skin. 
** Vesicant: needs central access
** Irritant: can be given peripherally 
* Does my patient need a port/picc?** If vesicant; for continuous infusions over several days (e.g. 5-FU); some patients with difficult access may request. 
*Advantages of ports: ** Easy access for labs
** Easy access for chemotherapy/fluids
* Disadvantages: ** Risk of infection
** Risk of thrombosis 
* General overview of chemotherapy side effects: ** Going to target the fastest growing cells in the body, which includes cells that line the GI tract, skin, hair/nails, and blood cells
** Therefore side effects are related: *** GI: nausea/vomiting, diarrhea (sometimes constipation), decreased appetite, taste changes
*** Low blood counts **** WBC nadir ~10-14 days (generally), and recover 21-28 days after chemo
* What about unique side effects of chemotherapy classes? How do we keep them straight?** We love keeping “Chemoman” from the USMLE study days in mind!
* Anthracycline*** MOA: Topoisomerase inhibitors
*** Ends in “rubicin”
*** You might hear people call doxorubicin the “red devil”
*** Used in lots of cancers
*** Hair loss occurs with this one
*** Known to cause cytopenias and associated with higher nausea potential 
*** Unique side effects: **** Heart failure (always get baseline echo!)
**** Development of MDS and leukemia 
* Alkylating agents** MOA: Drugs add alkyl group to the guanine base of the DNA molecule, preventing linking of strands
** End in “fosfamide”
** fosfamide or cyclophosphamide (AKA cytoxan)
** Used in lots of cancers
** Known to cause cytopenias and hair loss
** Unique side effects:*** Secondary MDS or leukemia possible 
*** Ifosfamide = neurotoxicity = methylene blue antidote
*** Cyclophosphamide = hemorrhagic cystitis due to acrolein byproduct accumulation = prevent by giving mesna to protect bladder
* Antimetabolites** MOA: Purine analog, pyrimidine analog, folate antagonists; therefore prevent production of base pairs or binds instead of normal base pairs
** End in “abine” - capecitabine, cytarabine, gemcitabine, cladribine, fludarabine
** Also 5-FU and 6-MP in this category so “number followed by dash”
 ** Unique side effects:*** Think bone marrow suppression in this category 
* Platinum agents** MOA: Believed to cause cross-linking of DNA
** End in “platin”
** Associated with high risk of neuropathy 
** Unique side effects: *** Cisplatin: **** Nephrotoxicity 
**** Ototoxicity 
**** High risk of nausea; need special prophylaxis 
*** Carboplatin: cytopenias
*** Oxaliplatin: higher rates GI side effects 
* Microtubule agents** MOA: Impair microtubule function, therefore impacting cell division
** End in “taxel” or vincristine/vinblastine (“V-stine”)
** Unique side effects: Neuropathy
Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

I read from cyclogenesis to cyclophosphamide.     Please be careful around cyclones. https://en.wikipedia.org/wiki/Cyclone     The word of the episode is "cyclone cellar".     Theme music from Tom Maslowski https://zestysol.com/     Merchandising! https://www.teepublic.com/user/spejampar     "The Dictionary - Letter A" on YouTube   "The Dictionary - Letter B" on YouTube   "The Dictionary - Letter C" on YouTube     Featured in a Top 10 Dictionary Podcasts list! https://blog.feedspot.com/dictionary_podcasts/     Backwards Talking on YouTube: https://www.youtube.com/playlist?list=PLmIujMwEDbgZUexyR90jaTEEVmAYcCzuq     dictionarypod@gmail.com https://www.facebook.com/thedictionarypod/ https://twitter.com/dictionarypod https://www.instagram.com/dictionarypod/ https://www.patreon.com/spejampar https://www.tiktok.com/@spejampar 917-727-5757

Rosalina and Shauna take you through the beginning stage of their chemotherapy treatments. This was recorded at the beginning of their chemotherapy journey of May/June 2021. They discuss conversations with their doctors about treatment plans and their struggle to cope with the reality of undergoing chemotherapy. They also explain their decisions and the reasons they chose to Cold Cap. Both Rosalina and Shauna decided to undergo chemotherapy, where Rosalina's treatment is Taxotere and Cyclophosphamide (TC), and Shauna's treatment is Adriamycin and Cyclophosphamide plus Taxol (AC-T).If you enjoy this episode, please share it with your friends. Help us reach more women by subscribing and rating us on Apple Podcast and Spotify.You can follow us on Instagram @TYFTSpodcast and email us at tyftspodcast@gmail.comResources below:Fast Mimicking Diet:-https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190229/-DIY FMD https://www.quantifiedbob.com/fasting-mimicking-diet/-https://www.breastcancer.org/research-news/intermittent-fasting-may-help-cancer-treatments-work-better-https://www.aacr.org/about-the-aacr/newsroom/news-releases/fasting-mimicking-diet-is-safe-may-modulate-metabolism-and-boost-antitumor-immunity-in-cancer-patients/Chemotherapy:-(AC)https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/chemotherapy/ac-chemotherapy-Taxotere https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/docetaxel-taxotere-Cold Cappinghttps://www.breastcancer.org/treatment/side_effects/hair-loss/cold-caps-scalp-cooling

The Filtrate:Joel TopfSwapnil HiremathNayan AroraJennie LinJoshua WaitzmanSpecial GuestsAlfred Kim assistant Professor at Washington University, director of the lupus clinic. Receives support from Arena Pharmaceuticals, manufacturer of volcloosporin, or at least he did before this episode aired.Dawn Castor assistant professor at The University of Louisville School of Medicine. She is on the speaker bureau for Arena Pharmaceuticals, manufacturer of volcloosporin. She was a site principle investigator (PI) as well as an author of the trial.EditorNayan AroraShow Notes:NIH Cyclophosphamide trial, long term follow-up: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Other important publications on this trial include:Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs NEJM 1986Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 1992Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamideVoclosporin is approved by FDA in January 2021Previous Lupus Nephritis podcast with Dawn and Alfred: Freely Filtered 029: Belimumab for lupus nephritisRituximab în Lupus. The LUNAR Trial (Spoiler, it didn't work): Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studySystematic review of the literature on reproducibility of the interpretation of renal biopsy in lupus nephritisConclusion The interpretation of renal biopsy in lupus nephritis is poorly reproducible, causing serious doubts about its validity and its clinical application. As it can lead to serious diagnosis, treatment and prognosis errors, it is necessary to intensify research in this field.The ALMS trials of mycohenolate mofetil (MMF) trials in lupus nephritisInduction: Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis (JASN 2009)Maintenance: Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis (NEJM 2011)Jacob deGrom on the mound. Baseball Reference. DeGrom is a two time Cy Young award winner, a 4-time All-Star and former Rookie of the Year winner.AURORA2: Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (ClinicalTrials.gov)Aurinia Pharmaceuticals.KDIGO 2021 Glomerulonephritis Guidelines Daily aspirin vs placebo for suspected acute myocardial infarction is highly protective except for patients born under Libra or Gemini. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient careMultitarget therapy for induction treatment of lupus nephritis: a randomized trial.Patient Benefits Justify Price of New Lupus Nephritis Drugs“The estimated annual price of belimumab is approximately $43,000 per patient; the estimated annual price for voclosporin is approximately $92,000 per patient.”2019 update of the EULAR recommendations for the management of systemic lupus erythematosus GuidelineDr. Glaucomflecken on TwitterCardiology vs Nephrology Round 1Nephrology vs Cardiology Round 2In the Heights (Wikipedia)The Mitchells vs. the Machines (Wikipedia)Paws in PrisonFlozinator pin

In this week's episode, we will learn more about the use of high-dose post-transplant cyclophosphamide in matched unrelated donors versus HLA haploidentical grafts, review prognostic factors and outcomes from the largest cohort of patients with angioimmunoblastic T-cell lymphoma reported to date, and look at a study that suggests that high molecular weight kininogen contributes to acetaminophen-induced liver injury.

Commentary by Dr. Seth Rotz

This episode covers cyclophosphamide and ifosfamide!

The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This month's selections include: Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study by Juan D. Cañete, Joan M. Nolla, Ruben Queiro, Miguel J. Rodríguez, Miguel Ruiz and Luis Lizán for the MERECES Working Gro DOI: https://doi.org/10.3899/jrheum.191056 Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic by Alfredo Aguirre, Laura Trupin, Mary Margaretten, Sarah Goglin, Jung Hee Noh and Jinoos Yazdany DOI: https://doi.org/10.3899/jrheum.190472 Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis by Edward P. Stern, Sandra G. Guerra, Harry Chinque, Vanessa Acquaah, David González-Serna, Markella Ponticos, Javier Martin, Voon H. Ong, Korsa Khan, Svetlana I. Nihtyanova, Mark Harber, Aine Burns, Maureen D. Mayes, Shervin Assassi, Carmen Fonseca and Christopher P. Denton DOI: https://doi.org/10.3899/jrheum.190945 Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study by Vincent Langlois, André Gillibert, Yurdagül Uzunhan, Marie-Laure Chabi, Eric Hachulla, Océane Landon-Cardinal, Kuberaka Mariampillai, Nicolas Champtiaux, Hilario Nunes, Olivier Benveniste and Baptiste Hervier DOI: https://doi.org/10.3899/jrheum.190505 Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus by Stanley Moore, Hsin-Hsuan Juo, Christoffer T. Nielsen, Helena Tyden, Anders A. Bengtsson and Christian Lood DOI: https://doi.org/10.3899/jrheum.190875 To read the full articles visit www.jrheum.org Music by David Hilowitz

(Actualidad Médica 013) El lupus eritematoso sistémico tiene una presentación, curso y pronóstico variable. Se actualizan las recomendaciones realizadas en el 2008.ENLACE: https://ard.bmj.com/content/78/6/736

(Actualidad Médica 012) Alrededor del 40% de los pacientes con lupus eritematoso sistémico pueden desarrollar enfermedad renal, que es una de las principales causas de morbilidad. Debido a su importancia se actualizan las recomendaciones realizadas en el 2012 para el manejo de nefritis lúpica.ENLACE: https://ard.bmj.com/content/early/2020/03/27/annrheumdis-2020-216924

Audio abstract for the published article: Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II by Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin and Robert M. Elashoff The Journal of Rheumatology October 2019, 46 (10) 1316-1325; DOI: https://doi.org/10.3899/jrheum.180441

(Cápsula 033) La ciclofosfamida pertenece al grupo de los medicamentos alquilantes. Estos usualmente se han utilizado para tratar diferentes tipos de cáncer debido al bloqueo que causan en la producción del material genético de las células, llevando a la muerte de estas.Por su gran capacidad para reducir la respuesta inmunitaria su uso se extendió a la reumatología, sobre todo para tratar complicaciones o casos graves.

Welcome To The MedFlashGo Podcast. This Is Your Daily 4 Minutes Or Less Rapid Review For USMLE, COMLEX, And Shelf Exams. In this question of the day, Sean discusses polyarteritis nodosa and a potential complication of treatment with cyclophosphamide. These questions are powered by MedFlashGo The First Voice-based interactive medical question bank currently available on Alexa. This tool allows medical students to study medical topics and be interactively tested without the use of a screen. You can study on your couch, in your car, and on the move without the use of a screen. To get access to your 50 free questions go on to your Alexa application and search medflashgo In the skills section. To learn more details go to medflashgo.com and check out our frequently asked questions section. Please know that these questions were creatively designed by medical students and physicians for the purpose of education and do not replace health information given from your health professionals. We have tried our best to make sure the information is accurate please, so please let us know if you find any errors and we will be sure to correct them. --- Send in a voice message: https://anchor.fm/medflashgo/message

Now it's time to start fighting this thing. My chemotherapy would be every “RCHOP” (Rituxan, Cyclophosphamide, Doxorubicin, Oncovin, Prednisone) every twenty-one days and Neulasta. --- Support this podcast: https://anchor.fm/josalynscancerstory/support

Stefan K. Barta, MD, of the University of Pennsylvania, joins David Henry, MD, to discuss the treatment and diagnosis of lymphoma in patients with HIV.    In this week's Clinical Correlation, Ilana Yurkiewicz, MD, has Part 2 of her discussion on informed consent in cancer. Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford University and is also a columnist for Hematology News. More from Dr. Yurkiewicz here. Notes, Transcripts, Links  Show notes By Emily Bryer, DO Resident in the department of internal medicine, University of Pennsylvania.  Immunosuppression in patients with HIV, especially with low CD4 counts, is associated with the development of lymphomas.  Diffuse large B-cell lymphoma is the most common lymphoma in patients with HIV followed by Burkitt lymphoma and Hodgkin lymphoma.  Extra-nodal manifestations of lymphoma are more common in patients with HIV, especially with lower CD4 counts. Following pathologic diagnosis, staging of lymphoma should include: CT scan PET scan Evaluation of CNS (MRI brain and LP) Bone marrow biopsy Evaluation for hepatitis B and C co-infection. Fluorescence in situ hybridization (FISH) is a molecular technique that identifies portions of DNA and helps to identify translocations and rearrangements. cMYC, BCL2, and BCL6 are all pro-proliferative genes and commonly implicated in lymphoma. cMYC rearrangement pose higher risk of CNS involvement and CNS relapse.  cMYC rearrangement (as opposed to cMYC translocation) requires therapy that is more aggressive therapy than R-CHOP.  Treatment of high grade diffuse large B-cell lymphoma: R-EPOCH Ibrutinib plus R-EPOCH Resources/Links: AIDS Malignancy Consortium Blood. 2004;103:275-82. Blood. 2010 Apr 15; 115(15): 3008-16. Clinical Trial: NCT03220022  Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas  

Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.

Dr. Rosenblum Discusses Anesthetic concerns in disease states such as: Scleroderma SLE Dermatomyositis Lyme's Disease Temporaral Arteritis and more!   Subscribe to our mailing list * indicates required Email Address *   AnesthesiaExam Podcast App For iPhone and Android DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment.  You should regularly consult a physician in matters relating to yours or another’s health.  You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional.    Copyright © 2015 QBazaar.com, LLC  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author.  

Welcome back!  Before we talk about cellcept for lupus nephritis, I decided we should flash back to 1996 and discuss one of the early trials that brought us cyclophosphamide.  It's a quick discussion that will help set us up nicely for ALMS this Sunday.  Remember to follow us on Twitter @JBRheum for updates! Access the paper here.

Dr Eljertsen speaks with ecancertv at SABCS 2016 about a trial regimen for the treatment of early breast cancer, of 3 cycles of epirubicin and cyclophosphamide (EC) before 3 cycles of docetaxel and cyclophosphamide (CD), compared to 6 cycles of the latter. He describes the addition of anthracyclin treatment as having no clinical benefit for patients with a non-mutated TOP2 gene, resulting only in increased toxicity. Given that Dr Eljertsen estimates only 15% of tumours express a TOP2a mutation, added anthracyclin treatment ought to be deferred in the majority of patients.

Dr Boccia speaks with ecancer at the 16th International Myeloma Workshop about the CHAMPION-2 study. The study evaluated different dose levels of carfilzomib in combination with fixed-dose cyclophosphamide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). Carfilzomib is a selective and irreversible second-generation proteasome inhibitor. Carfilzomib (56 mg/m2) twice weekly combined with cyclophosphamide and dexamethasone had manageable toxicity and was effective for treating patients with newly diagnosed MM.

Donald Tashkin discusses a clinical trial for the treatment of scleroderma-related interstitial lung disease, a rare but devastating condition.

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Cyclophosphamide is used in many different types of childhood cancer. This episode describes how it is given, for which diseases, and possible side effects.

Conventional GVHD prophylaxis with calcineurin inhibitors has a high incidence of chronic GVHD. Kanakri et al show that post-transplant administration of High dose cyclophosphamide is an effective way of reducing chronic GVHD. Limitations of this approach and alternative approaches are briefly discussed.

Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 25, 2014 issue

Dr Annamaria Brioli talks to ecancer at the 18th EHA Congress in Stockholm, Sweden about two studies that examine the use of cyclophosphamide lenalidomide and dexamethasone in myeloma. The first study analysed toxicity and the second looked at primary malignancy.

Prof Keating talks to ecancer at the 2012 European Haematology Association conference in Amsterdam. He covers how to treat chronic lymphocytic leukaemia (CLL), which can be often best left alone. He suggests that the current best treatment is the FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen. Another option is the BR (Bendamustine, Rituximab) regimen which has yet to be fully tested. 17p deletion type CLL unfortunately has a much worse outcomes than other CLL types. Prof Keating also covers alemtuzumab, allogeneic stem cell transplant and new molecule PCI32765 as an oral medication.

Oncology, December 13th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide STEPHEN JONES, US Oncology Research, Houston REFERENCE: ABSTRACT 12 Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.

CPA is an anticancer drug that can be applied in conventional tumor therapy, in combination with gene transfer and in antiangiogenic approaches with low dose metronomically scheduled regimes. In the context of metronomic CPA therapy, acrolein was shown to exhibit antiangiogenic effects and therapeutic contribution has to be reconsidered. Despite improved treatment regimes, drug resistance will be still an obstacle in chemotherapeutic regimes due to different escape mechanisms; progress in the development of new strategies might be achieved by suitable in vitro models such as the agarose overlay system or agarose wrapped microspheroids.

Background: Paravasation is a rare but severe complication of treatment with cytotoxic agents. Some anticancer drugs are considered to be of high toxicity (vesicant), some are merely irritant, and some are regarded as nearly non-toxic to healthy tissue as is the case with cyclophosphamide. Case Report: In this report, we present the first case of severe tissue damage caused by a paravasation of cyclophosphamide in a breast cancer patient receiving chemotherapy. Conclusion: Therefore, every attending oncological physician should be aware of the possibility of severe tissue damage as a consequence of cyclophosphamide paravasation.